发明名称 Treatment of neurological deficits in the striatum or substanta nigra pars compacta
摘要 The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.
申请公布号 US8846394(B2) 申请公布日期 2014.09.30
申请号 US200812268647 申请日期 2008.11.11
申请人 Ethicon, Inc. 发明人 Mistry Sanjay;Messina Darin J.
分类号 C12N5/07;A61K38/18;A61K38/17 主分类号 C12N5/07
代理机构 代理人
主权项 1. A method for differentiating cells isolated from mammalian umbilical cord tissue substantially free of blood towards a dopaminergic phenotype, comprising treating the cells isolated from mammalian umbilical cord tissue substantially free of blood with a composition comprising human recombinant GDF5, Sonic Hedgehog, retinoic acid and FGF8 in an amount sufficient to induce the cells isolated from mammalian umbilical cord tissue substantially free of blood to differentiate towards a dopaminergic phenotype.
地址 Somerville NJ US
您可能感兴趣的专利